Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

499 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrative systems biology reveals NKG2A-biased immune responses correlate with protection in infectious disease, autoimmune disease, and cancer.
Chen DG, Xie J, Choi J, Ng RH, Zhang R, Li S, Edmark R, Zheng H, Solomon B, Campbell KM, Medina E, Ribas A, Khatri P, Lanier LL, Mease PJ, Goldman JD, Su Y, Heath JR. Chen DG, et al. Among authors: mease pj. Cell Rep. 2024 Mar 26;43(3):113872. doi: 10.1016/j.celrep.2024.113872. Epub 2024 Feb 29. Cell Rep. 2024. PMID: 38427562 Free PMC article.
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.
Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Choi O, Krol Y, Gottlieb AB. Ogdie A, et al. Among authors: mease pj. BMC Rheumatol. 2024 May 21;8(1):20. doi: 10.1186/s41927-024-00386-7. BMC Rheumatol. 2024. PMID: 38773563 Free PMC article.
Machine learning to understand risks for severe COVID-19 outcomes: a retrospective cohort study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US health-care system.
Wei Q, Mease PJ, Chiorean M, Iles-Shih L, Matos WF, Baumgartner A, Molani S, Hwang YM, Belhu B, Ralevski A, Hadlock J. Wei Q, et al. Among authors: mease pj. Lancet Digit Health. 2024 May;6(5):e309-e322. doi: 10.1016/S2589-7500(24)00021-9. Lancet Digit Health. 2024. PMID: 38670740 Free PMC article.
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2.
Navarro-Compán V, Ramiro S, Deodhar A, Mease PJ, Rudwaleit M, de la Loge C, Fleurinck C, Taieb V, Mørup MF, Massow U, Kay J, Magrey M. Navarro-Compán V, et al. Among authors: mease pj. RMD Open. 2024 Apr 10;10(2):e004040. doi: 10.1136/rmdopen-2023-004040. RMD Open. 2024. PMID: 38599650 Free PMC article. Clinical Trial.
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
Coates LC, Gossec L, Zimmermann M, Shawi M, Rampakakis E, Shiff NJ, Kollmeier AP, Xu XL, Nash P, Mease PJ, Helliwell PS. Coates LC, et al. Among authors: mease pj. RMD Open. 2024 Mar 26;10(1):e003977. doi: 10.1136/rmdopen-2023-003977. RMD Open. 2024. PMID: 38531621 Free PMC article. Clinical Trial.
Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial.
Strand V, Gossec L, Coates LC, Ogdie A, Choi J, Becker B, Zhuo J, Lehman T, Nowak M, Elegbe A, Mease PJ, Deodhar A. Strand V, et al. Among authors: mease pj. Arthritis Care Res (Hoboken). 2024 Mar 26. doi: 10.1002/acr.25333. Online ahead of print. Arthritis Care Res (Hoboken). 2024. PMID: 38529674
499 results